(90)y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)

Arne Kolstad, Anna Laurell, Niels S. Andersen, Erkki Elonen, Riikka Raty, Lone Bredo Pedersen, Annika Loft, Trond Velde Bogsrud, Marie Nordstrom, Dorte Gillstrom, Per Boye Hansen, Hans Bentzen, Unn-Merete Fagerli, Peter Meyer, Herman Nilsson-Ehle, Mats Jerkeman, Anne Kristine Lehmann, Grete F. Lauritzsen, Christer Sundstrom, Jan DelabieMarja-Liisa Karjalainen-Lindsberg, Elisabeth Ralfkiaer, Mats Ehinger, Christian H. Geisler

Research output: Contribution to journalPublished meeting abstractpeer-review

Original languageEnglish
Pages (from-to)384-384
JournalBlood
Volume114
Issue number22
Publication statusPublished - 2009
Event51st Annual Meeting of the American-Society-of-Hematology - New Orleans, LA
Duration: 2009 Dec 52009 Dec 8

Bibliographical note

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Oncology, MV (013035000), Pathology, (Lund) (013030000)

Subject classification (UKÄ)

  • Hematology

Cite this